Nanobiotix Stock Up +826% Over the Year and Remains in Technical Equilibrium Zone

Nanobiotix Regains Ground After Recent Pullback

Nanobiotix stock is regaining height this Friday after a decline of 2.26% over the last seven days, which had interrupted a significant upward sequence. The quarterly performance remains remarkable, at +50.79% over three months, while the annual increase reaches 826.6%. Technically, the price at €26.78 is situated in the middle of the Bollinger Bands, with the upper bound at €29.70 and the lower bound at €24.47, indicating neither an overbought nor oversold situation. The RSI, at 48, confirms this equilibrium position and signals a lack of marked directional tension in the short term. The stock trades significantly above its 50-day moving average (€24.37), a gap that reflects the bullish momentum observed in recent months. The most relevant resistance threshold is located at €33.50, about 25% above the current price.

Notable Stability Despite Year-Long Surge

Remarkably for a stock that has experienced such a surge over a year, Nanobiotix's monthly volatility stands at 23.46%, a moderate level for a biotech of this market capitalization. The beta of the stock, at 0.09, indicates an almost total decorrelation with major indices, making it a unique case on the Paris stock exchange. In the healthcare sector, listed peers in Europe show mixed variations this Friday: Sanofi is up 0.41% while UCB gains 0.96% during the session. The SBF 120, the index to which Nanobiotix belongs, is up 0.23% mid-morning. No events are scheduled in the company's financial calendar in the short term, and the absence of identified catalysts allows the stock to evolve on its own dynamics. The current configuration places the price in an intermediate zone between its support at €21.95 and its resistance at €33.50, after a consolidation phase that had brought the stock below its 20-day moving average (€27.08).